Europe Internal Neurostimulation Devices Market - Industry Trends Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143143
- Pages: 225
-
Format:
Short Description:
Europe Internal Neurostimulation Devices Market, By Product Type (Spinal Cord Stimulation (SCS), Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, and Gastric Electric Stimulation), Distribution Channel (Direct Tender and Third Party Service Provider), Country (Germany, U.K., Italy, Spain, France, Switzerland, Belgium, Netherlands, Russia, Turkey and Rest of Europe) Industry Trends and Forecast to 2029
Market Definition:
An internal neurostimulation device is a surgically placed device. It delivers mild electrical signals to the epidural space near your spine through one or more thin wires called leads. Neurostimulation provides pain relief by disrupting the pain signals traveling between the spinal cord and the brain.
Neurostimulation devices include invasive and noninvasive approaches involving electrical stimulation to drive neural function within a circuit. The increased demand for internal neurostimulation devices is due to next-generation technological progressions in the neurostimulation devices, providing much-needed therapeutic relief to an unprecedented number of people affected by debilitating neurologic and psychiatric disorders worldwide. The rise of modern-day neuromodulation therapies has increased over half a century, rich with serendipitous discoveries and technological advances that have led to different neurostimulation strategies. Within the past two decades, innovation in medical device technology has begun to drive the evolution of these neurostimulation systems at a more accelerated pace
The convenient internal neurostimulation device used by the patients is vagus nerve stimulation. The vagus neurostimulation device uses a device to stimulate the vagus nerve with electrical impulses. An implantable vagus nerve stimulator is currently FDA-approved to treat epilepsy and depression. There's one vagus nerve on each side of the body, running from the brainstem through the neck to the chest and abdomen. In the future, software advancements such as closed-loop stimulation and remote programming will enable internal neurostimulation devices to be a more personalized and accessible technology. The future of internal neurostimulation devices is expected to improve quality of life further.
Market Segmentation:
The Europe internal neurostimulation devices market is categorized into product type and distribution channel.
On the basis of product type, the Europe internal neurostimulation devices market is segmented into spinal cord stimulation (SCS), deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, gastric electric stimulation
On the basis of distribution channel, the Europe internal neurostimulation devices market is segmented into direct tender and third party service provider
Market Players:
Some key market players operating in the Europe internal neurostimulation devices market are listed below:
Medtronic
LivaNova PLC
Abbott
Microsemi (a subsidiary of Microchip Technology Inc.)
Boston Scientific Corporation
Inspire Medical Systems, Inc.
Integer Holdings Corporation
Finetech Medical
ALEVA NEUROTHERAPEUTICS
OptoGenTech GmbH.
INBRAIN NEUROELECTRONICS
Neuronano AB
NEURIMPULSE s.r.l.
Newronika S.p.A.
NEVRO CORP.
Nalu Medical, Inc.
Valencia Technologies
CIRTEC
Sequana Medical NV
BIOINDUCTION
ONWARD
Axonics, Inc.
Mainstay Medical
TABLE OF CONTENTS
1 INTRODUCTION 67
1.1 OBJECTIVES OF THE STUDY 67
1.2 MARKET DEFINITION 67
1.3 OVERVIEW OF EUROPE INTERNAL NEUROSTIMULATION DEVICES MARKET 67
1.4 CURRENCY AND PRICING 70
1.5 LIMITATION 70
1.6 MARKETS COVERED 70
2 MARKET SEGMENTATION 75
2.1 MARKETS COVERED 75
2.2 GEOGRAPHIC SCOPE 76
2.3 YEARS CONSIDERED FOR THE STUDY 77
2.4 CURRENCY AND PRICING 77
2.5 RESEARCH METHODOLOGY 78
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 81
2.7 DBMR MARKET POSITION GRID 82
2.8 THE CATEGORY VS TIME GRID 84
2.9 SECONDARY SOURCES 85
2.10 ASSUMPTIONS 85
3 EXECUTIVE SUMMARY 86
4 PREMIUM INSIGHTS 88
4.1 PESTEL 89
4.2 PORTER'S FIVE FORCES MODEL 90
4.3 PIPELINE ANALYSIS FOR INTERNAL NEUROSTIMULATION DEVICES MARKET 91
5 REGULATIONS OF EUROPE INTERNAL NEUROSTIMULATION DEVICES MARKET 93
6 EPIDEMIOLOGY OF DISEASES 95
6.1 INCIDENCE OF ISCHEMIA 95
6.2 INCIDENCE OF PARKINSON'S DISEASE 95
6.3 INCIDENCE OF FAILED BACK SYNDROME 96
6.4 INCIDENCE OF TREMOR 96
6.5 INCIDENCE OF DEPRESSION 97
6.6 INCIDENCE OF URINE INCONTINENCE 97
6.7 INCIDENCE OF FECAL INCONTINENCE 98
6.8 INCIDENCE RATE OF EPILEPSY 98
6.9 INCIDENCE OF GASTROPARESIS 99
6.10 PREVALENCE OF OBESITY 100
7 EPIDEMIOLOGY OF NEUROSTIMULATION PROCEDURES 102
7.1 NUMBER OF SPINAL CORD STIMULATION (SCS) PROCEDURES 102
7.1.1 NUMBER OF TEST PROCEDURES 102
7.1.2 NUMBER OF IMPLANTATION PROCEDURES 102
7.2 NUMBER OF DEEP BRAIN STIMULATION PROCEDURES 102
7.3 NUMBER OF VAGUS NERVE STIMULATION PROCEDURES 102
7.4 NUMBER OF SACRAL NEVER STIMULATION PROCEDURES 103
7.5 NUMBER OF TRANSCRANIAL MAGNETIC STIMULATION (TMS) PROCEDURES 103
7.6 NUMBER OF INTERMITTENT THETA BURST STIMULATION (ITBS) PROCEDURES 103
7.7 NUMBER OF TRANSCRANIAL DIRECT ELECTRICAL STIMULATION (TDCS) PROCEDURES 104
8 MARKET OVERVIEW 105
8.1 DRIVERS 107
8.1.1 RISE IN PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS 107
8.1.2 DEMAND FOR INTERNAL NEUROSTIMULATION DEVICES AS A ADD ON THERAPY 108
8.1.3 INCREASED FUNDING FOR THE NEUROSTIMULATION DEVICES 108
8.1.4 TECHNOLOGICAL ADVANCEMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES 108
8.1.5 RISE IN PRODUCT APPROVALS 109
8.2 RESTRAINTS 110
8.2.1 RISE IN COST OF THE DEEP BRAIN STIMULATION DEVICES 110
8.2.2 RISKS NOTICED WHILE USING THE INTERNAL NEUROSTIMULATION DEVICES 110
8.2.3 RISE IN PRODUCT RECALL 110
8.2.4 AVAILABILITY OF ALTERNATE IMAGING DIAGNOSTIC DEVICES 111
8.3 OPPORTUNITIES 111
8.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 111
8.3.2 RECENT PRODUCT DEVELOPMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES 112
8.3.3 DEMAND FOR MINIMALLY INVASIVE SURGERY 112
8.4 CHALLENGES 113
8.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES 113
8.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS 113
9 EUROPE INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE 114
9.1 OVERVIEW 115
9.2 SPINAL CORD STIMULATION 118
9.2.1 SPINAL CORD STIMULATION, BY TYPE 119
9.2.1.1 BATTERY 119
9.2.1.1.1 RECHARGEABLE 120
9.2.1.1.2 NON-RECHARGEABLE 120
9.2.1.2 LEAD 120
9.2.1.2.1 PERCUTANEOUS 121
9.2.1.2.2 PADDLE 121
9.2.2 SPINAL CORD STIMULATION, BY APPLICATION 121
9.2.2.1 ISCHEMIA 121
9.2.2.2 CHRONIC LOW BACK PAIN (CLBP) 121
9.2.2.3 DIABETIC NEUROPATHY 122
9.2.2.4 FAILED BACK SYNDROME 122
9.3 DEEP BRAIN STIMULATION 122
9.3.1 DEEP BRAIN STIMULATION, BY TYPE 123
9.3.1.1 SINGLE CHANNEL DEEP BRAIN STIMULATOR 124
9.3.1.2 DOUBLE CHANNEL DEEP BRAIN STIMULATOR 124
9.3.1.3 BATTERY 124
9.3.1.3.1 RECHARGEABLE 125
9.3.1.3.2 NON-RECHARGEABLE 125
9.3.1.4 LEAD 125
9.3.2 DEEP BRAIN STIMULATION, BY APPLICATION 125
9.3.2.1 PARKINSONS DISEASE 126
9.3.2.2 TREMOR 126
9.3.2.3 DEPRESSION 126
9.4 SACRAL NERVE STIMULATION 126
9.4.1 SACRAL NERVE STIMULATION, BY TYPE 127
9.4.1.1 BATTERY 128
9.4.1.2 LEAD 128
9.5 SACRAL NERVE STIMULATION, BY APPLICATION 128
9.5.1 URINE INCONTINENCE 128
9.5.2 FECAL INCONTINENCE 129
9.6 VAGUS NERVE STIMULATION 129
9.6.1 VAGUS NERVE STIMULATION, BY TYPE 130
9.6.1.1 BATTERY 131
9.6.1.2 LEAD 131
9.6.2 VAGUS NERVE STIMULATION, BY APPLICATION 131
9.6.2.1 EPILEPSY 131
9.6.2.2 OTHERS 131
9.7 GASTRIC ELECTRICAL STIMULATION 131
9.7.1 GASTRIC ELECTRICAL STIMULATION, BY TYPE 132
9.7.1.1 BATTERY 133
9.7.1.2 LEAD 133
9.7.2 GASTRIC ELECTRICAL STIMULATION, BY APPLICATION 133
9.7.2.1 GASTROPARESIS 134
9.7.2.2 OTHERS 134
10 EUROPE INTERNAL NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL 135
10.1 OVERVIEW 136
10.2 DIRECT TENDER 138
10.3 THIRD PARTY PROVIDER 139
11 EUROPE INTERNAL NEUROSTIMULATION DEVICES MARKET, BY REGION 141
11.1 EUROPE 142
11.1.1 GERMANY 154
11.1.2 U.K. 162
11.1.3 ITALY 170
11.1.4 SPAIN 178
11.1.5 FRANCE 186
11.1.6 SWITZERLAND 194
11.1.7 BELGIUM 202
11.1.8 NETHERLANDS 210
11.1.9 RUSSIA 218
11.1.10 TURKEY 226
11.1.11 REST OF EUROPE 234
12 EUROPE INTERNAL NEUROSTIMULATION DEVICES MARKET: COMPANY LANDSCAPE 235
12.1 COMPANY SHARE ANALYSIS: EUROPE 235
13 SWOT ANALYSIS 236
14 COMPANY PROFILE 237
14.1 MEDTRONIC (2021) 237
14.1.1 COMPANY SNAPSHOT 237
14.1.2 REVENUE ANALYSIS 237
14.1.3 COMPANY SHARE ANALYSIS 238
14.1.4 PRODUCT PORTFOLIO 238
14.1.5 RECENT DEVELOPMENTS 239
14.2 BOSTON SCIENTIFIC CORPORATION (2021) 240
14.2.1 COMPANY SNAPSHOT 240
14.2.2 REVENUE ANALYSIS 241
14.2.3 COMPANY SHARE ANALYSIS 241
14.2.4 PRODUCT PORTFOLIO 242
14.2.5 RECENT DEVELOPMENTS 242
14.3 ABBOTT (2021) 244
14.3.1 COMPANY SNAPSHOT 244
14.3.2 REVENUE ANALYSIS 244
14.3.3 COMPANY SHARE ANALYSIS 245
14.3.4 PRODUCT PORTFOLIO 245
14.3.5 RECENT DEVELOPMENTS 246
14.4 LIVANOVA PLC (2021) 247
14.4.1 COMPANY SNAPSHOT 247
14.4.2 REVENUE ANALYSIS 247
14.4.3 COMPANY SHARE ANALYSIS 248
14.4.4 PRODUCT PORTFOLIO 248
14.4.5 RECENT DEVELOPMENTS 248
14.5 NEVRO CORP. (2021) 250
14.5.1 COMPANY SNAPSHOT 250
14.5.2 REVENUE ANALYSIS 250
14.5.3 COMPANY SHARE ANALYSIS 251
14.5.4 PRODUCT PORTFOLIO 251
14.5.5 RECENT DEVELOPMENTS 252
14.6 AXONICS, INC. 253
14.6.1 COMPANY SNAPSHOT 253
14.6.2 REVENUE ANALYSIS 253
14.6.3 PRODUCT PORTFOLIO 254
14.6.4 RECENT DEVELOPMENTS 254
14.7 ALEVA NEUROTHERAPEUTICS 255
14.7.1 COMPANY SNAPSHOT 255
14.7.2 PRODUCT PORTFOLIO 255
14.7.3 RECENT DEVELOPMENTS 255
14.8 BIONIC VISION TECHNOLOGIES. 256
14.8.1 COMPANY SNAPSHOT 256
14.8.2 PRODUCT PORTFOLIO 256
14.8.3 RECENT DEVELOPMENTS 256
14.9 BLUEWIND MEDICAL 257
14.9.1 COMPANY SNAPSHOT 257
14.9.2 PRODUCT PORTFOLIO 257
14.9.3 RECENT DEVELOPMENTS 257
14.10 BIOINDUCTION 258
14.10.1 COMPANY SNAPSHOT 258
14.10.2 PRODUCT PORTFOLIO 258
14.10.3 RECENT DEVELOPMENT 258
14.11 CIRTEC 259
14.11.1 COMPANY SNAPSHOT 259
14.11.2 PRODUCT PORTFOLIO 259
14.11.3 RECENT DEVELOPMENTS 260
14.12 FINETECH MEDICAL 261
14.12.1 COMPANY SNAPSHOT 261
14.12.2 PRODUCT PORTFOLIO 261
14.12.3 RECENT DEVELOPMENTS 261
14.13 GIMER MEDICAL 262
14.13.1 COMPANY SNAPSHOT 262
14.13.2 PRODUCT PORTFOLIO 262
14.13.3 RECENT DEVELOPMENTS 262
14.14 INSPIRE MEDICAL SYSTEMS, INC. 263
14.14.1 COMPANY SNAPSHOT 263
14.14.2 REVENUE ANALYSIS 263
14.14.3 PRODUCT PORTFOLIO 264
14.14.4 RECENT DEVELOPMENTS 264
14.15 INTEGER HOLDINGS CORPORATION 265
14.15.1 COMPANY SNAPSHOT 265
14.15.2 REVENUE ANALYSIS 265
14.15.3 PRODUCT PORTFOLIO 266
14.15.4 RECENT DEVELOPMENT 266
14.16 INBRAIN NEUROELECTRONICS 267
14.16.1 COMPANY SNAPSHOT 267
14.16.2 PRODUCT PORTFOLIO 267
14.16.3 RECENT DEVELOPMENT 267
14.17 MAINSTAY MEDICAL 268
14.17.1 COMPANY SNAPSHOT 268
14.17.2 REVENUE ANALYSIS 268
14.17.3 PRODUCT PORTFOLIO 269
14.17.4 RECENT DEVELOPMENTS 269
14.18 MICROSEMI (A WHOLLY OWNDED SUBSIDIARY OF MICROCHIP TECHNOLOGY INC.) 270
14.18.1 COMPANY SNAPSHOT 270
14.18.2 REVENUE ANALYSIS 270
14.18.3 PRODUCT PORTFOLIO 271
14.18.4 RECENT DEVELOPMENTS 271
14.19 MICROTRANSPONDER INC 272
14.19.1 COMPANY SNAPSHOT 272
14.19.2 PRODUCT PORTFOLIO 272
14.19.3 RECENT DEVELOPMENT 272
14.20 MICRO-LEADS 273
14.20.1 COMPANY SNAPSHOT 273
14.20.2 PRODUCT PORTFOLIO 273
14.20.3 RECENT DEVELOPMENT 273
14.21 NALU MEDICAL, INC 274
14.21.1 COMPANY SNAPSHOT 274
14.21.2 PRODUCT PORTFOLIO 274
14.21.3 RECENT DEVELOPMENT 274
14.22 NEURONANO AB 275
14.22.1 COMPANY SNAPSHOT 275
14.22.2 PRODUCT PORTFOLIO 275
14.22.3 RECENT DEVELOPMENTS 275
14.23 NEURIMPULSE S.R.L. 276
14.23.1 COMPANY SNAPSHOT 276
14.23.2 PRODUCT PORTFOLIO 276
14.23.3 RECENT DEVELOPMENTS 276
14.24 NEWRONIKA S.P.A. 277
14.24.1 COMPANY SNAPSHOT 277
14.24.2 PRODUCT PORTFOLIO 277
14.24.3 RECENT DEVELOPMENTS 277
14.25 OPTOGENTECH GMBH. 278
14.25.1 COMPANY SNAPSHOT 278
14.25.2 PRODUCT PORTFOLIO 278
14.25.3 RECENT DEVELOPMENTS 278
14.26 ONWARD 279
14.26.1 COMPANY SNAPSHOT 279
14.26.2 PRODUCT PORTFOLIO 279
14.26.3 RECENT DEVELOPMENT 279
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
